Global Rofecoxib 麻豆原创 Research Report 2024

Publication ID:

PB502243831

Publication Date:

March 6, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Rofecoxib is a COX-2 selective nonsteroidal anti-inflammatory drug (NSAID). It was marketed by Merck & Co. to treat osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, acute pain conditions, migraine, and dysmenorrhea.Rofecoxib was available by prescription in both tablet-form and as an oral suspension.
The global Rofecoxib market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Rofecoxib is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Rofecoxib is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Rofecoxib include Merck, Chengdu Meinkai Chemical Co. LTD, Wuhan Xinxin Jiali Biotechnology Co. LTD, Hubei TuoChu Kang Yuan Pharmaceutical Chemical Co. LTD, Pfizer and Tremeau, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Rofecoxib, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Rofecoxib.
Report Scope
The Rofecoxib market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Rofecoxib market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Rofecoxib manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Merck
Chengdu Meinkai Chemical Co. LTD
Wuhan Xinxin Jiali Biotechnology Co. LTD
Hubei TuoChu Kang Yuan Pharmaceutical Chemical Co. LTD
Pfizer
Tremeau
Segment by Type
Oral Suspension.
Tablet-Form
Segment by Application
Osteoarthritis
Rheumatoid Arthritis
Juvenile Rheumatoid Arthritis
Acute Pain Conditions
Migraine
Dysmenorrhea
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Rofecoxib manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Rofecoxib in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Rofecoxib 麻豆原创 Overview
1.1 Product Overview and Scope of Rofecoxib
1.2 Rofecoxib Segment by Type
1.2.1 Global Rofecoxib 麻豆原创 Value Comparison by Type (2024-2030)
1.2.2 Oral Suspension.
1.2.3 Tablet-Form
1.3 Rofecoxib Segment by Application
1.3.1 Global Rofecoxib 麻豆原创 Value by Application: (2024-2030)
1.3.2 Osteoarthritis
1.3.3 Rheumatoid Arthritis
1.3.4 Juvenile Rheumatoid Arthritis
1.3.5 Acute Pain Conditions
1.3.6 Migraine
1.3.7 Dysmenorrhea
1.4 Global Rofecoxib 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Rofecoxib Revenue 2019-2030
1.4.2 Global Rofecoxib Sales 2019-2030
1.4.3 Global Rofecoxib 麻豆原创 Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Rofecoxib 麻豆原创 Competition by Manufacturers
2.1 Global Rofecoxib Sales 麻豆原创 Share by Manufacturers (2019-2024)
2.2 Global Rofecoxib Revenue 麻豆原创 Share by Manufacturers (2019-2024)
2.3 Global Rofecoxib Average Price by Manufacturers (2019-2024)
2.4 Global Rofecoxib Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Rofecoxib, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Rofecoxib, Product Type & Application
2.7 Rofecoxib 麻豆原创 Competitive Situation and Trends
2.7.1 Rofecoxib 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Rofecoxib Players 麻豆原创 Share by Revenue
2.7.3 Global Rofecoxib 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Rofecoxib Retrospective 麻豆原创 Scenario by Region
3.1 Global Rofecoxib 麻豆原创 Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Rofecoxib Global Rofecoxib Sales by Region: 2019-2030
3.2.1 Global Rofecoxib Sales by Region: 2019-2024
3.2.2 Global Rofecoxib Sales by Region: 2025-2030
3.3 Global Rofecoxib Global Rofecoxib Revenue by Region: 2019-2030
3.3.1 Global Rofecoxib Revenue by Region: 2019-2024
3.3.2 Global Rofecoxib Revenue by Region: 2025-2030
3.4 North America Rofecoxib 麻豆原创 Facts & Figures by Country
3.4.1 North America Rofecoxib 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Rofecoxib Sales by Country (2019-2030)
3.4.3 North America Rofecoxib Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Rofecoxib 麻豆原创 Facts & Figures by Country
3.5.1 Europe Rofecoxib 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Rofecoxib Sales by Country (2019-2030)
3.5.3 Europe Rofecoxib Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Rofecoxib 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Rofecoxib 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Rofecoxib Sales by Country (2019-2030)
3.6.3 Asia Pacific Rofecoxib Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Rofecoxib 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Rofecoxib 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Rofecoxib Sales by Country (2019-2030)
3.7.3 Latin America Rofecoxib Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Rofecoxib 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Rofecoxib 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Rofecoxib Sales by Country (2019-2030)
3.8.3 Middle East and Africa Rofecoxib Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Rofecoxib Sales by Type (2019-2030)
4.1.1 Global Rofecoxib Sales by Type (2019-2024)
4.1.2 Global Rofecoxib Sales by Type (2025-2030)
4.1.3 Global Rofecoxib Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global Rofecoxib Revenue by Type (2019-2030)
4.2.1 Global Rofecoxib Revenue by Type (2019-2024)
4.2.2 Global Rofecoxib Revenue by Type (2025-2030)
4.2.3 Global Rofecoxib Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global Rofecoxib Price by Type (2019-2030)
5 Segment by Application
5.1 Global Rofecoxib Sales by Application (2019-2030)
5.1.1 Global Rofecoxib Sales by Application (2019-2024)
5.1.2 Global Rofecoxib Sales by Application (2025-2030)
5.1.3 Global Rofecoxib Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global Rofecoxib Revenue by Application (2019-2030)
5.2.1 Global Rofecoxib Revenue by Application (2019-2024)
5.2.2 Global Rofecoxib Revenue by Application (2025-2030)
5.2.3 Global Rofecoxib Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global Rofecoxib Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Corporation Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck Rofecoxib Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Merck Rofecoxib Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 Chengdu Meinkai Chemical Co. LTD
6.2.1 Chengdu Meinkai Chemical Co. LTD Corporation Information
6.2.2 Chengdu Meinkai Chemical Co. LTD Description and Business Overview
6.2.3 Chengdu Meinkai Chemical Co. LTD Rofecoxib Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Chengdu Meinkai Chemical Co. LTD Rofecoxib Product Portfolio
6.2.5 Chengdu Meinkai Chemical Co. LTD Recent Developments/Updates
6.3 Wuhan Xinxin Jiali Biotechnology Co. LTD
6.3.1 Wuhan Xinxin Jiali Biotechnology Co. LTD Corporation Information
6.3.2 Wuhan Xinxin Jiali Biotechnology Co. LTD Description and Business Overview
6.3.3 Wuhan Xinxin Jiali Biotechnology Co. LTD Rofecoxib Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Wuhan Xinxin Jiali Biotechnology Co. LTD Rofecoxib Product Portfolio
6.3.5 Wuhan Xinxin Jiali Biotechnology Co. LTD Recent Developments/Updates
6.4 Hubei TuoChu Kang Yuan Pharmaceutical Chemical Co. LTD
6.4.1 Hubei TuoChu Kang Yuan Pharmaceutical Chemical Co. LTD Corporation Information
6.4.2 Hubei TuoChu Kang Yuan Pharmaceutical Chemical Co. LTD Description and Business Overview
6.4.3 Hubei TuoChu Kang Yuan Pharmaceutical Chemical Co. LTD Rofecoxib Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Hubei TuoChu Kang Yuan Pharmaceutical Chemical Co. LTD Rofecoxib Product Portfolio
6.4.5 Hubei TuoChu Kang Yuan Pharmaceutical Chemical Co. LTD Recent Developments/Updates
6.5 Pfizer
6.5.1 Pfizer Corporation Information
6.5.2 Pfizer Description and Business Overview
6.5.3 Pfizer Rofecoxib Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Pfizer Rofecoxib Product Portfolio
6.5.5 Pfizer Recent Developments/Updates
6.6 Tremeau
6.6.1 Tremeau Corporation Information
6.6.2 Tremeau Description and Business Overview
6.6.3 Tremeau Rofecoxib Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Tremeau Rofecoxib Product Portfolio
6.6.5 Tremeau Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Rofecoxib Industry Chain Analysis
7.2 Rofecoxib Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Rofecoxib Production Mode & Process
7.4 Rofecoxib Sales and 麻豆原创ing
7.4.1 Rofecoxib Sales Channels
7.4.2 Rofecoxib Distributors
7.5 Rofecoxib Customers
8 Rofecoxib 麻豆原创 Dynamics
8.1 Rofecoxib Industry Trends
8.2 Rofecoxib 麻豆原创 Drivers
8.3 Rofecoxib 麻豆原创 Challenges
8.4 Rofecoxib 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Merck
Chengdu Meinkai Chemical Co. LTD
Wuhan Xinxin Jiali Biotechnology Co. LTD
Hubei TuoChu Kang Yuan Pharmaceutical Chemical Co. LTD
Pfizer
Tremeau

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.